BKI1 Regulates Plant Architecture through Coordinated Inhibition of the Brassinosteroid and ERECTA Signaling Pathways in Arabidopsis.
BKI1 Regulates Plant Architecture through Coordinated Inhibition of the Brassinosteroid and ERECTA Signaling Pathways in Arabidopsis.
复制标题
DOI：
10.1016/j.molp.2016.11.014
复制
发表时间：
2017-02
期刊：
影响因子：
27.5
通讯作者：
Dongxu Wang;Cangjing Yang;Haijiao Wang;Zhi-yi Wu;Jianjun Jiang;Jingjing Liu;Zhuona He;F. Chang;Hong Ma;Xuelu Wang
中科院分区：
文献类型：
--
作者：
Dongxu Wang;Cangjing Yang;Haijiao Wang;Zhi-yi Wu;Jianjun Jiang;Jingjing Liu;Zhuona He;F. Chang;Hong Ma;Xuelu Wang
数百种富含亮氨酸重复序列的受体样激酶（LRR-RLKs）在植物的发育和生理过程中发挥着重要作用。控制LRR-RLKs处于基础和非活动状态的机制是必要的，但很少研究。BKI 1是目前报道的唯一一种拟南芥受体激酶抑制剂，它在油菜素类固醇途径中负调控BRI 1。在这项研究中，我们发现BKI 1也可以与另一个重要的LRR-RLK，ERECTA（ER）相互作用。表型分析表明，BKI 1和ER一起调节植物的结构，包括花梗的方向，这是一个新报道的表型BR和ER介导的发育过程。基因表达分析表明，BKI 1调节ER应答基因的子集。激酶试验表明BKI 1抑制ER激酶活性。此外，BKI 1对ER信号传导的抑制作用的释放很大程度上依赖于BRI 1的激活。我们的数据为RLK的调节和激活提供了重要的见解，并表明BKI 1作为BRI 1和ER信号通路的共同抑制剂发挥作用。
Hundreds of leucine-rich repeat receptor-like kinases (LRR-RLKs) play indispensable roles in a wide range of plant developmental and physiological processes. The mechanisms controlling LRR-RLKs at a basal and inactive status are essential but rarely studied. BKI1 is the only reported inhibitor of receptor kinases inArabidopsis, which negatively regulates BRI1 in the brassinosteroid pathway. In this study, we found that BKI1 can also interact with another important LRR-RLK, ERECTA (ER). Phenotypic analysis showed that BKI1 and ER together regulate plant architecture, including pedicel orientation, which is a newly reported phenotype in the BR- and ER-mediated developmental processes. Gene expression analysis revealed that BKI1 regulates a subset of ER-responsive genes. Kinase assays demonstrated that BKI1 inhibits ER kinase activity. In addition, the release of BKI1 inhibition on ER signaling relies largely on BRI1 activation. Our data provide significant insights into the regulation and activation of RLKs and suggest that BKI1 functions as a common suppressor of the BRI1 and ER signaling pathways.